Community-acquired pneumonia primary prevention: Difference between revisions

Jump to navigation Jump to search
Chetan Lokhande (talk | contribs)
Chetan Lokhande (talk | contribs)
Line 9: Line 9:
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''Factor''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Pneumococcal polysaccharide vaccine'''
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''Factor''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Pneumococcal polysaccharide vaccine'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Route of administration''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Intramuscular injection'''''
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Route of administration''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸   '''''Intramuscular injection'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Type of vaccine''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''Bacterial component (polysaccharide capsule)'''''
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Type of vaccine''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''Bacterial component (polysaccharide capsule)'''''
Line 19: Line 19:
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left |&nbsp;▸&nbsp;'''''Revaccination schedule''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''One-time revaccination after 5 years for <br> ▸ (1) adults 65 years of age, if the first dose is received before age 65 years<br> ▸ (2) persons with asplenia <br>▸ (3) immunocompromised persons'''''
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left |&nbsp;▸&nbsp;'''''Revaccination schedule''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''One-time revaccination after 5 years for <br> ▸ (1) adults 65 years of age, if the first dose is received before age 65 years<br> ▸ (2) persons with asplenia <br>▸ (3) immunocompromised persons'''''
|-
|-
|}
|}


Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.<ref name="Harper-2005">{{Cite journal  | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi =  | PMID = 16086456 }}</ref>
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.<ref name="Harper-2005">{{Cite journal  | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi =  | PMID = 16086456 }}</ref>

Revision as of 21:28, 29 January 2014

Pneumonia Main Page

Community-Acquired Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Community-acquired pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Severity Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Ultrasound

Other Diagnostic Studies

Treatment

Hospital Admission Decision

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Community-acquired pneumonia primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Community-acquired pneumonia primary prevention

CDC on Community-acquired pneumonia primary prevention

Community-acquired pneumonia primary prevention in the news

Blogs on Community-acquired pneumonia primary prevention

Directions to Hospitals Treating Community-acquired pneumonia

Risk calculators and risk factors for Community-acquired pneumonia primary prevention

Vaccines

Pneumococcal Polysaccharide Vaccine

Vaccine prevention of community-acquired pneumonia.[1]
Factor Pneumococcal polysaccharide vaccine
 ▸ Route of administration Intramuscular injection
 ▸ Type of vaccine Bacterial component (polysaccharide capsule)
 ▸ Recommended groups All persons ≥ 65 years of age
'High-risk persons 2–64 years of age'
'Current smokers'
 ▸ Specific high-risk indications for vaccination Chronic cardiovascular, pulmonary, renal, or liver disease
Diabetes mellitus
Cerebrospinal fluid leaks
Alcoholism
Asplenia
Immunocompromising conditions / medications
Native Americans and Alaska natives
Long-term care facility residents
 ▸ Revaccination schedule One-time revaccination after 5 years for
▸ (1) adults 65 years of age, if the first dose is received before age 65 years
▸ (2) persons with asplenia
▸ (3) immunocompromised persons

Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.[1]

References

  1. 1.0 1.1 Harper, SA.; Fukuda, K.; Uyeki, TM.; Cox, NJ.; Bridges, CB. (2005). "Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 54 (RR-8): 1–40. PMID 16086456. Unknown parameter |month= ignored (help)

Template:WH Template:WS